At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,179 enrolled
Drug / intervention
Famciclovir +3 moredrug
Likely dose
Famciclovir 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes
In Brief
A Phase 3 clinical trial evaluating Famciclovir, Valacyclovir, and 2 other interventions for Genital Herpes. Completed, enrolled 1,179 participants across 66 sites in 4 countries.
Detailed Summary
This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Herpes
CountriesAustralia, Canada, Germany, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMar 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedMar 24, 2006
Enrollment StartMar 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.3 years ago
Interventions
Famciclovirdrug
Famciclovir 500 mg tablet
Valacyclovirdrug
Valacyclovir 500 mg capsule
Placebo matching famciclovirdrug
Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
Placebo matching valacyclovirdrug
Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.